Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (HER2) and hormone receptor expression in uterine papillary serous carcinoma

Cancer Science

Volumn 103, Issue 5, 2012, Pages 926-932

  Togami, Shinichi ^a   Sasajima, Yuko ^a,b   Oi, Takateru ^a   Ishikawa, Mitsuya ^a   Onda, Takashi ^c   Ikeda, Shun Ichi ^a   Kato, Tomoyasu ^a   Tsuda, Hitoshi ^a   Kasamatsu, Takahiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b TEIKYO UNIVERSITY   (Japan)

^c KITASATO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; GENERAL PATHOLOGICAL PARAMETERS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; SURVIVAL RATE; UTERINE PAPILLARY SEROUS CARCINOMA; UTERUS CARCINOMA;

AGED; AGED, 80 AND OVER; CARCINOMA, PAPILLARY; CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; UTERINE NEOPLASMS;

EID: 84860226762     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02240.x     Document Type: Article

References (42)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-30.
2. Nakao Y, Yokoyama M, Hara K et al. MR imaging in endometrial carcinoma as a diagnostic tool for the absence of myometrial invasion. Gynecol Oncol 2006; 102: 343-7.
3. Kothari R, Morrison C, Richardson D et al. The prognostic significance of the triple negative phenotype in endometrial cancer. Gynecol Oncol 2010; 118: 172-5.
4. Hendrickson M, Ross J, Eifel PJ, Cox RS, Martinez A, Kempson R. Adenocarcinoma of the endometrium: analysis of 256 cases with carcinoma limited to the uterine corpus. Pathology review and analysis of prognostic variables. Gynecol Oncol 1982; 13: 373-92.
5. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982; 6: 93-108.
6. Nicklin JL, Copeland LJ. Endometrial papillary serous carcinoma: patterns of spread and treatment. Clin Obstet Gynecol 1996; 39: 686-95.
7. Slomovitz BM, Burke TW, Eifel PJ et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol 2003; 91: 463-9.
8. Bristow RE, Asrari F, Trimble EL, Montz FJ. Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (Stage I-III) disease. Gynecol Oncol 2001; 81: 279-86.
9. Carcangiu ML, Chambers JT. Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma. Gynecol Oncol 1992; 47: 298-305.
10. Grice J, Ek M, Greer B et al. Uterine papillary serous carcinoma: evaluation of long-term survival in surgically staged patients. Gynecol Oncol 1998; 69: 69-73.
11. Meric-Bernstam F, Hung MC. Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy. Clin Cancer Res 2006; 12: 6326-30.
12. Rabindran SK. Antitumor activity of HER-2 inhibitors. Cancer Lett 2005; 227: 9-23.
13. Friedlander E, Barok M, Szollosi J, Vereb G. ErbB-directed immunotherapy: antibodies in current practice and promising new agents. Immunol Lett 2008; 116: 126-40.
14. Creasman WT. Prognostic significance of hormone receptors in endometrial cancer. Cancer 1993; 71: 1467-70.
15. Fukuda K, Mori M, Uchiyama M, Iwai K, Iwasaka T, Sugimori H. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma. Gynecol Oncol 1998; 69: 220-5.
16. Nyholm HC, Christensen IJ, Nielsen AL. Progesterone receptor levels independently predict survival in endometrial adenocarcinoma. Gynecol Oncol 1995; 59: 347-51.
17. Pertschuk LP, Masood S, Simone J et al. Estrogen receptor immunocytochemistry in endometrial carcinoma: a prognostic marker for survival. Gynecol Oncol 1996; 63: 28-33.
18. Sobin LH, Wittekind C, eds. TNM Classification of Malignant Tumours, 6th edn. Hoboken, NJ: John Wiley & Sons, 2002.
19. Silverberg S, Mutter GL, Kurman RJ, Kubik-Huch RA, Nogales F, Tavassoli FA. Tumours of the uterine corpus. In: Tavassoli FA, Devilee P, eds. World Health Organization Classification of Tumours. Tumours of the Breast and Female Genital Organs. Lyon: IARC Press, 2003; 224-7.
20. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155-68.
21. Goldberg H, Miller RC, Abdah-Bortnyak R et al. Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN). Gynecol Oncol 2008; 108: 298-305.
22. Low JS, Wong EH, Tan HS et al. Adjuvant sequential chemotherapy and radiotherapy in uterine papillary serous carcinoma. Gynecol Oncol 2005; 97: 171-7.
23. FIGO (International Federation of Gynecology and Obstetrics) annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2003; 83(Suppl. 1): ix-xxii, 1-229.
24. Wang W, Do V, Hogg R et al. Uterine papillary serous carcinoma: patterns of failure and survival. Aust N Z J Obstet Gynaecol 2009; 49: 419-25.
25. Bristow RE, Duska LR, Montz FJ. The role of cytoreductive surgery in the management of Stage IV uterine papillary serous carcinoma. Gynecol Oncol 2001; 81: 92-9.
26. Goff BA, Kato D, Schmidt RA et al. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol 1994; 54: 264-8.
27. Odicino FE, Bignotti E, Rossi E et al. HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization. Int J Gynecol Cancer 2008; 18: 14-21.
28. Konecny G, Pauletti G, Pegram M et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003; 95: 142-53.
29. Menard S, Valagussa P, Pilotti S et al. Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. J Clin Oncol 2001; 19: 329-35.
30. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
31. Halperin R, Zehavi S, Habler L, Hadas E, Bukovsky I, Schneider D. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium. Eur J Gynaecol Oncol 2001; 22: 122-6.
32. Santin AD, Bellone S, Van Stedum S et al. Determination of HER2/neu status in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry and fluorescence in situ hybridization. Gynecol Oncol 2005; 98: 24-30.
33. Slomovitz BM, Broaddus RR, Burke TW et al. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol 2004; 22: 3126-32.
34. Konecny GE, Santos L, Winterhoff B et al. HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (Type II) endometrial cancer. Br J Cancer 2009; 100: 89-95.
35. Ferrandina G, Ranelletti FO, Gallotta V et al. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer. Gynecol Oncol 2005; 98: 383-9.
36. Jazaeri AA, Nunes KJ, Dalton MS, Xu M, Shupnik MA, Rice LW. Well-differentiated endometrial adenocarcinomas and poorly differentiated mixed mullerian tumors have altered ER and PR isoform expression. Oncogene 2001; 20: 6965-9.
37. Kadar N, Malfetano JH, Homesley HD. Steroid receptor concentrations in endometrial carcinoma: effect on survival in surgically staged patients. Gynecol Oncol 1993; 50: 281-6.
38. Alkushi A, Irving J, Hsu F et al. Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray. Virchows Arch 2003; 442: 271-7.
39. Alkushi A, Kobel M, Kalloger SE, Gilks CB. High-grade endometrial carcinoma: serous and Grade 3 endometrioid carcinomas have different immunophenotypes and outcomes. Int J Gynecol Pathol 2010; 29: 343-50.
40. Kounelis S, Kapranos N, Kouri E, Coppola D, Papadaki H, Jones MW. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature. Mod Pathol 2000; 13: 379-88.
41. Sherman ME, Bitterman P, Rosenshein NB, Delgado G, Kurman RJ. Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol 1992; 16: 600-10.
42. Badve S, Dabbs DJ, Schnitt SJ et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol 2011; 24: 157-67.